Journal List > J Korean Ophthalmol Soc > v.55(10) > 1009801

Kim and Lee: Clinical and Microbiological Analysis of Gram-Positive Bacterial Keratitis, a 15-Year Review

Abstract

Purpose

To investigate the shifting trends of pathogenic organisms, antibiotic resistance, and clinical characteristics of patients with Gram-positive bacterial keratitis and to elucidate the prognostic factors.

Methods

We performed a retrospective chart review of 152 isolates in 146 eyes with Gram-positive bacterial keratitis between January 1998 and December 2012. The study was divided into 5 periods for analysis of the bacteriological profiles and in vitro antibiotic resistance. The epidemiological and clinical characteristics were compared according to bacterial isolates. Logistic regression analysis was performed to determine the risk factors.

Results

Gram-positive bacterial keratitis tended to decrease and significant change in the distribution of isolates was not observed. Commonly isolated organisms were S. epidermidis (48.7%), S. aureus (25.0%), and S. pneumoniae (7.2%) in order of frequency. The resistance to fluoroquinolone tended to increase (p = 0.104) and resistance to gentamicin was significantly decreased (p = 0.01). S. epidermidis had the shortest corneal epithelium healing time (p = 0.035) and the most favorable visual outcome after treatment (p = 0.035) compared with the other species. Risk factors for poor visual outcomes included a best corrected visual acuity less than 0.1 at initial evaluation and an epithelial healing time greater than 10 days.

Conclusions

Gram-positive bacterial keratitis tended to decrease and S. epidermidis was the most common isolate. The clinical prognosis was most favorable in S. epidermidis. The BCVA less than 0.1 at initial evaluation was an important risk factor for poor visual outcome and surgical treatment in Gram-positive bacterial keratitis.

References

1. Lichtinger A, Yeung SN, Kim P, et al. Shifting trends in bacterial keratitis in Toronto: an 11-year review. Ophthalmology. 2012; 19:1785–90.
2. Armstrong RA. The microbiology of the eye. Ophthalmic Physiol Opt. 2000; 20:429–41.
crossref
3. Schaefer F, Bruttin O, Zografos L, Guex-Crosier Y. Bacterial keratitis: a prospective clinical and microbiological study. Br J Ophthalmol. 2001; 85:842–7.
crossref
4. Liesegang TJ, Forster RK. Spectrum of microbial keratitis in South Florida. Am J Ophthalmol. 1980; 90:38–47.
crossref
5. Sun HJ, Lee JY, Kim SY, Jung MS. Clinical features of infectious keratitis in west coast area of Chungcheongnam-do, Korea. J Korean Ophthalmol Soc. 2010; 51:658–63.
crossref
6. Lim SH, Lee SB. Analysis of inpatients with bacterial keratitis over a 12-year period: pathogenic organisms and antibiotic resistance. J Korean Ophthalmol Soc. 2012; 53:372–84.
crossref
7. Hahn YH, Lee SJ, Hahn TW, et al. Antibiotic susceptibilities of ocular isolates from patients with bacterial keratitis: a multi-center study. J Korean Ophthalmol Soc. 1999; 40:2401–10.
8. Kim WJ, Kweon EY, Lee DW, et al. Prognostic factor and antibiotic susceptibility in bacterial keratitis: results of an eight-year period. J Korean Ophthalmol Soc. 2009; 50:1495–504.
crossref
9. Fong CF, Hu FR, Tseng CH, et al. Antibiotic susceptibility of bacterial isolates from bacterial keratitis cases in a university hospital in Taiwan. Am J Ophthalmol. 2007; 144:682–9.
crossref
10. Shalchi Z, Gurbaxani A, Baker M, Nash J. Antibiotic resistance in microbial keratitis: ten-year experience of corneal scrapes in the United Kingdom. Ophthalmology. 2011; 118:2161–5.
crossref
11. Toshida H, Kogure N, Inoue N, Murakami A. Trends in microbial keratitis in Japan. Eye Contact Lens. 2007; 33:70–3.
crossref
12. Zhang C, Liang Y, Deng S, et al. Distribution of bacterial keratitis and emerging resistance to antibiotics in China from 2001 to 2004. Clin Ophthalmol. 2008; 2:575–9.
13. Yeh DL, Stinnett SS, Afshari NA. Analysis of bacterial cultures in infectious keratitis, 1997 to 2004. Am J Ophthalmol. 2006; 142:1066–8.
crossref
14. Mantadakis E, Maraki S, Michailidis L, et al. Antimicrobial susceptibility of Gram-positive cocci isolated from patients with conjunctivitis and keratitis in Crete, Greece. J Microbiol Immunol Infect. 2013; 46:41–7.
crossref
15. Green MD, Apel AJ, Naduvilath T, Stapleton FJ. Clinical outcomes of keratitis. Clin Experiment Ophthalmol. 2007; 35:421–6.
crossref
16. Park JH, Lee SB. Analysis on inpatients with infectious keratitis: causative organisms, clinical aspects and risk factors. J Korean Ophthalmol Soc. 2009; 50:1152–66.
crossref
17. Kim SJ, Lee SB. Analysis on elderly inpatients with infectious keratitis: causative organisms, clinical aspects, and risk factors. J Korean Ophthalmol Soc. 2010; 51:1554–67.
crossref
18. Kim JY, Yoon KC, Park YG, et al. Age-related clinical analysis of infectious keratitis in two tertiary centers. J Korean Ophthalmol Soc. 2010; 51:927–34.
crossref
19. Yoon JH, Jung JW, Moon HS, et al. Antibiotics susceptibility in bacterial keratitis and proper initial treatment. J Korean Ophthalmol Soc. 2013; 54:38–45.
crossref
20. Mukerji N, Vajpayee RB, Sharma N. Technique of area measurement of epithelial defects. Cornea. 2003; 22:549–51.
crossref
21. Biemer JJ. Antimicrobial susceptibility testing by the Kirby-Bauer disc diffusion method. Ann Clin Lab Sci. 1973; 3:135–40.
22. Jorgensen JH, Hindler JF. New consensus guidelines from the Clinical and Laboratory Standards Institute for antimicrobial susceptibility testing of infrequently isolated or fastidious bacteria. Clin Infect Dis. 2007; 44:280–6.
crossref
23. Shin SY, Koo SH, Kwon KC, et al. Evaluation of the Vitek 2 Korean antimicrobial susceptibility testing cards AST N056 and AST N055. Korean J Clin Microbiol. 2008; 11:23–8.
crossref
24. Bourcier T, Thomas F, Borderie V, et al. Bacterial keratitis: predisposing factors, clinical and microbiological review of 300 cases. Br J Ophthalmol. 2003; 87:834–8.
crossref
25. Gopinathan U, Sharma S, Garg P, Rao GN. Review of epidemiological features, microbiological diagnosis and treatment outcome of microbial keratitis: experience of over a decade. Indian J Ophthalmol. 2009; 57:273–9.
crossref
26. Jeong JG, Kweon EY, Cho NC, You IC. Comparison of methicillin-sensitive Staphylococcus epidermidis (MSSE) keratits and methicillin-resistant Staphylococcus epidermidis (MRSE) keratitis. J Korean Ophthalmol Soc. 2011; 52:930–5.
27. Sotozono C, Inagaki K, Fujita A, et al. Methicillin-resistant Staphylococcus aureus and methicillin-resistant Staphylococcus epidermidis infections in the cornea. Cornea. 2002; 21(7 Suppl):S94–101.
crossref
28. Fridkin SK, Hageman JC, Morrison M, et al. Methicillin-resistant Staphylococcus aureus disease in three communities. N Engl J Med. 2005; 352:1436–44.
29. Adebayo A, Parikh JG, McCormick SA, et al. Shifting trends in in vitro antibiotic susceptibilities for common bacterial conjunctival isolates in the last decade at the New York Eye and Ear Infirmary. Graefes Arch Clin Exp Ophthalmol. 2011; 249:111–9.
crossref
30. Chalita MR, Höfling-Lima AL, Paranhos A Jr, et al. Shifting trends in in vitro antibiotic susceptibilities for common ocular isolates during a period of 15 years. Am J Ophthalmol. 2004; 137:43–51.
crossref
31. Solomon R, Donnenfeld ED, Perry HD, et al. Penetration of topically applied gatifloxacin 0.3%, moxifloxacin 0.5%, and ciprofloxacin 0.3% into the aqueous humor. Ophthalmology. 2005; 112:466–9.
crossref
32. Mather R, Karenchak LM, Romanowski EG, Kowalski RP. Fourth generation fluoroquinolones: new weapons in the arsenal of ophthalmic antibiotics. Am J Ophthalmol. 2002; 133:463–6.
33. Kim BK, Lee DW, Cho NC, You IC. Clinical aspect and prognosis of Staphylococcus epidermidis keratitis. J Korean Ophthalmol Soc. 2011; 52:14–22.
34. Jang YS, Hahn YH. Epidemiology of Staphylococcus epidermidis keratitis. J Korean Ophthalmol Soc. 2002; 43:665–71.
35. Vajpayee RB, Dada T, Saxena R, et al. Study of the first contact management profile of cases of infectious keratitis: a hospital-based study. Cornea. 2000; 19:52–6.
crossref
36. Ong SJ, Huang YC, Tan HY, et al. Staphylococcus aureus keratitis: a review of hospital cases. PLoS One. 2013; 8:e80119.
crossref
37. Green M, Apel A, Stapleton F. Risk factors and causative organisms in microbial keratitis. Cornea. 2008; 27:22–7.
crossref
38. Hahn YH, Hahn TW, Tchah H, et al. Epidemiology of infectious keratitis (II): a multi-center study. J Korean Ophthalmol Soc. 2001; 42:247–65.
39. Lowy FD, Hammer SM. Staphylococcus epidermidis infections. Ann Intern Med. 1983; 99:834–9.
crossref
40. Parmar P, Salman A, Kalavathy CM, et al. Pneumococcal keratitis: a clinical profile. Clin Experiment Ophthalmol. 2003; 31:44–7.
crossref
41. Charteris DG, Batterbury M, Armstrong M, Tullo AB. Suppurative keratitis caused by Streptococcus pneumoniae after cataract surgery. Br J Ophthalmol. 1994; 78:847–9.
crossref
42. Ormerod LD, Hertzmark E, Gomez DS, et al. Epidemiology of microbial keratitis in southern California. A multivariate analysis. Ophthalmology. 1987; 94:1322–33.
43. Scott IU, Loo RH, Flynn HW Jr, Miller D. Endophthalmitis caused by Enterococcus faecalis: antibiotic selection and treatment outcomes. Ophthalmology. 2003; 110:1573–7.
44. Busbee BG, Recchia FM, Kaiser R, et al. Bleb-associated endophthalmitis: clinical characteristics and visual outcomes. Ophthalmology. 2004; 111:1495–503. discussion 1503.
45. Lee SM, Lee JH. A case of Enterococcus faecalis endophthalmitis with corneal ulcer. Korean J Ophthalmol. 2004; 18:175–9.
crossref
46. Rau G, Seedor JA, Shah MK, et al. Incidence and clinical characteristics of Enterococcus keratitis. Cornea. 2008; 27:895–9.
crossref
47. Elitsur Y, Biedner BZ, Bar-Ziv J. Ethmoiditis, conjunctivitis, and orbital cellulitis due to Enterococcus infection. Clin Pediatr (Phila). 1984; 23:123.
48. Kim JT, Lee JK, Moon NJ, Cho HK. A case of Enterococcus faecalis endophthalmitis after phacoemulsification. J Korean Ophthalmol Soc. 2006; 47:1853–8.
49. Reynaud af Geijersstam A, Sorsa T, Stackelberg S, et al. Effect of E. faecalis on the release of serine proteases elastase and cathepsin G, and collagenase-2 (MMP-8) by human polymorphonuclear leukocytes (PMNs). Int Endod J. 2005; 38:667–77.
crossref
50. Peng CH, Cheng CK, Chang CK, Chen YL. Multiresistant Enterococci: a rare cause of complicated corneal ulcer and review of the literature. Can J Ophthalmol. 2009; 44:214–5.
crossref
51. Zirakzadeh A, Patel R. Vancomycin-resistant Enterococci: colonization, infection, detection, and treatment. Mayo Clin Proc. 2006; 81:529–36.
crossref
52. Maple PA, Hamilton-Miller JM, Brumfitt W. World-wide antibiotic resistance in methicillin-resistant Staphylococcus aureus. Lancet. 1989; 1:537–40.
crossref
53. Hsiao CH, Chuang CC, Tan HY, et al. Methicillin-resistant Staphylococcus aureus ocular infection: a 10-year hospital-based study. Ophthalmology. 2012; 119:522–7.
crossref
54. Waring GO III, Bouchard CS. A matrix of pathologic responses in the cornea. Krachmer JH, Mannis MJ, Holland EJ, editors. Cornea. 3rd ed.Philadelphia: Elsevier;2011. 1:chap. 5.
crossref
55. Miedziak AI, Miller MR, Rapuano CJ, et al. Risk factors in microbial keratitis leading to penetrating keratoplasty. Ophthalmology. 1999; 106:1166–70. discussion 1171.
crossref
56. Cho CH, Lee SB. Analysis of inpatients with contact lens related bacterial keratitis: causative microorganisms, clinical aspects, and prognostic factors. J Korean Ophthalmol Soc. 2013; 54:1327–38.
crossref
57. Musch DC, Sugar A, Meyer RF. Demographic and predisposing factors in corneal ulceration. Arch Ophthalmol. 1983; 101:1545–8.
crossref

Figure 1.
Prevalence of Gram-positive bacterial isolates in total bacterial keratitis during 1998-2012. The p-value was calculated using chi-square test to com pare the distribution of the Gram-positive bacterial isolates between 2 periods. *Gram-positive bacterial isolates significantly decreased between 2 periods.
jkos-55-1432f1.tif
Figure 2.
Organisms and shifting trend in Gram-positive bacterial isolates during 1998-2012. *Six eyes had mixed infection of 2 Gram-positive bacterial species (S. epidermidis & S. aureus (2 eyes), S. epidermidis & E. feacalis, S. epidermidis & S. sanguis, S. aureus & E. feacalis, S. dysgalactiae & S. pyogenes); The p-value was calculated using Spearman rank correlation coefficient to compare the distribution of the bacterial isolates for 15 years. CNS = coagulase-negative Staphylococcus.
jkos-55-1432f2.tif
Figure 3.
Trends in antimicrobial resistance of Gram-positive bacterial isolates. *The resistance of gentamicin decreased significantly (p = 0.01, Spearman rank correlation coefficient); N1 = number of isolates with resistance; N2 = number of tested isolates; The p-value was calculated using Spearman rank correlation coefficient to compare the distribution of the antimicrobial resistance for 15 years; §Total value of fluoroquinolone: ciprofloxacin (n = 70), norfloxacin (n = 21), levofloxacin (n = 25), and moxifloxacin (n = 21).
jkos-55-1432f3.tif
Figure 4.
Trends in antimicrobial resistance to oxacillin in S. epidermidis and S. aureus. Oxacillin resistance of S. epidermidis was significantly higher than that of S. aureus (p = 0.001, Chi-square test).
jkos-55-1432f4.tif
Table 1.
Demographics of Gram-positive bacterial keratitis according to the isolated microorganisms
No. of cases (%)
Characteristics All case S. epidermidis S. aureus Strepto. spp. Entero. spp.
(n = 146) (n = 74) (n = 38) (n = 22) (n = 16)
Sex (M:F) 1.11:1 1.24:1 1.24:1 1:1 1:1
Age (years)
 60≤ 68 (46.6) 28 (37.8)* 20 (52.6) 15 (68.2) 8 (50.0)
 40-59 44 (30.1) 29 (39.2)* 10 (26.3) 2 (9.1) 4 (25.0)
 20-39 22 (15.2) 13 (17.6)* 4 (10.5) 2 (9.1) 3 (18.8)
 <20 12 (8.2) 4 (5.4)* 4 (10.5) 3 (13.6) 1 (6.3)
Seasonal distribution
 Spring (Mar-May) 55 (37.7) 28 (37.8) 12 (31.6) 9 (40.9) 7 (43.8)
 Summer (Jun-Aug) 27 (18.5) 13 (17.6) 10 (26.3) 2 (9.1) 3 (18.8)
 Autumn (Sep-Nov) 30 (20.5) 14 (18.9) 6 (15.8) 7 (31.8) 3 (18.8)
 Winter (Dec-Feb) 34 (23.3) 19 (25.7) 10 (26.3) 4 (18.2) 3 (18.8)
Predisposing factors
 Trauma 53 (36.3) 31 (41.9) 9 (23.7) 9 (40.9) 5 (31.3)
 Previous ocular surface disease 45 (30.8) 21 (28.4) 14 (36.8) 7 (31.8) 6 (37.5)
 Previous ocular surgery 27 (18.5) 12 (16.2) 8 (21.1) 4 (18.2) 3 (18.8)
 Systemic disease 42 (28.8) 17 (23.0) 13 (34.2) 6 (27.3) 6 (37.5)
 Contact lens wear 8 (5.5) 5 (6.8) 2 (5.3) 1 (4.5) 1 (6.3)

Strepto. spp. = Streptococcus species; Entero. spp. = Enterococcus species.

* The p-value was < 0.05, which was calculated for comparison of proportions with all other groups by chi-square test;

Sum of the number of eyes with each subgroup does not add up to 100% because of overlap of subgroups and no history of identified predisposing factors.

Table 2.
Clinical characteristics at initial presentation, epithelial healing time, surgical treatment, and visual outcome of Gram-positive bacterial keratitis according to the isolated microorganisms
No. of cases (%)
Characteristics All cases S. epidermidis S. aureus Strepto. spp. Entero. spp.
(n = 146) (n = 74) (n = 38) (n = 22) (n = 16)
Corneal lesion
 Location
  Central 91 (62.3) 42 (56.8) 23 (60.5) 17 (77.3) 12 (75.0)
  Marginal 55 (37.7) 32 (43.2) 15 (39.5) 5 (22.7) 4 (25.0)
 Size
  <5 mm2 89 (61.0) 52 (68.4) 23 (60.5) 10 (45.5) 8 (50.0)
  ≥5 mm2 57 (39.0) 24 (31.6) 15 (39.5) 12 (54.5) 8 (50.0)
 Hypopyon
  No 105 (71.9) 56 (76.7) 26 (68.4) 14 (63.6) 11 (68.8)
  Yes 41 (28.1) 18 (24.3) 12 (31.6) 8 (36.4) 5 (31.3)
Epithelial healing time (n = 119) 10.8 ± 11.1 8.8 ± 11.1* 11.8 ± 8.6 13.6 ± 11.9 15.9 ± 14.4
Surgical treatment 22 (15.1) 11 (14.9) 7 (18.4) 4 (18.2) 4 (25.0)
Initial BCVA (Snellen acuity)
 <0.1 68 (46.6) 29 (39.2) 19 (50.0) 14 (63.6) 8 (50.0)
 0.1-0.5 54 (37.0) 33 (44.6) 14 (36.8) 4 (18.2) 6 (37.5)
 0.6-1.0 24 (16.4) 12 (16.2) 5 (13.2) 4 (18.2) 2 (12.5)
Final BCVA (Snellen acuity)
 <0.1 44 (30.1) 16 (21.7)* 14 (36.8) 10 (45.5) 8 (50.0)
 0.1-0.5 39 (26.7) 23 (31.1)* 10 (26.3) 5 (22.7) 2 (12.5)
 0.6-1.0 63 (43.2) 35 (47.3)* 14 (36.8) 7 (31.8) 6 (37.5)

Values are presented as mean ± SD unless otherwise indicated.

Strepto. spp. = Streptococcus species; Entero. spp. = Enterococcus species; BCVA = best corrected visual acuity.

* The p-value was < 0.05, which was calculated for comparison of proportions with all other groups by independent t-test or chi-square test;

‘Central’ is located within 1/2 radius from the center of the cornea, ‘Marginal’ is located within 1/2 radius from the limbus;

The eyes were excluded if surgical treatment was done (22 eyes) or the record for epithelial healing time was missed (5 eyes).

Table 3.
Comparisons of epidemiologic and clinical features and treatment outcome between MSS and MRS
Characteristics No. of cases (%)
p-value
MSS (n = 56) MRS (n = 56)
Sex (M:F) 1.24:1 1.24:1 1.000
Age (years) 0.399
 60≤ 21 (37.5) 27 (48.2)
 40-59 21 (37.5) 18 (32.1)
 20-39 11 (19.6) 6 (10.7)
 <20 3 (5.4) 5 (8.9)
Seasonal distribution 0.377
 Spring (Mar-May) 17 (30.4) 23 (41.1)
 Summer (Jun-Aug) 14 (25.0) 9 (16.1)
 Autumn (Sep-Nov) 12 (21.4) 8 (14.3)
 Winter (Dec-Feb) 13 (23.2) 16 (28.6)
Predisposing factors
 Trauma 15 (26.8) 25 (44.6) 0.049
 Previous ocular surface disease 18 (32.1) 17 (30.4) 0.838
 Previous ocular surgery 9 (16.1) 11 (19.6) 0.622
 Systemic disease 13 (23.2) 17 (30.4) 0.393
 Contact lens wear 5 (8.9) 2 (1.8) 0.438§
Corneal lesion
 Location* 0.566
  Central 34 (60.7) 31 (55.4)
  Marginal 22 (39.3) 25 (44.6)
 Size (mm2) 0.321
  <5 34 (60.7) 39 (69.6)
  ≥5 22 (39.3) 17 (30.4)
 Hypopyon 0.670
  No 40 (71.4) 42 (75.0)
  Yes 16 (28.6) 14 (25.0)
Epithelial healing time (n = 90) 11.1 ± 10.8 8.6 ± 9.9 0.259Π
Surgical treatment 12 (21.4) 6 (10.7) 0.123
Initial BCVA (Snellen acuity) 0.589
 <0.1 25 (44.6) 23 (41.1)
 0.1-0.5 24 (42.9) 22 (39.3)
 0.6-1.0 7 (12.5) 11 (19.6)
Final BCVA (Snellen acuity) 0.165
 <0.1 19 (33.9) 12 (21.4)
 0.1-0.5 12 (21.4) 20 (35.7)
 0.6-1.0 25 (44.6) 24 (42.9)

MSS = methicillin-sensitive Staphylococcus; MRS = methicillin-resistant Staphylococcus; BCVA = best corrected visual acuity.

* ‘Central’ is located within 1/2 radius from the center of the cornea, ‘Marginal’ is located within 1/2 radius from the limbus;

The eyes were excluded if surgical treatment was done (18 eyes) or the record for epithelial healing time was missed (4 eyes);

The p-value was calculated to compare the distribution between MSS and MRS by chi-square test;

§ Fisher's exact test;

Π independent t-test.

Table 4.
Risk factors for poor visual outcome and surgical treatment in Gram-positive bacterial keratitis (univariate logistic regression analysis)
Poor visual outcome
Surgical treatment
Factor No. of eyes (%)* OR 95% CI p-value No. of eyes (%) OR 95% CI p-value
(n = 45) (n = 22)
Sex
 Female 19/69 (27.5) 1.00 10/69 (14.5) 1.00
 Male 26/77 (33.8) 1.34 0.66-2.72 0.416 12/77 (15.6) 1.09 0.43-2.70 0.854
Cultured organisms 0.061 0.802
S. epidermidis 16/74 (21.6) 1.00 11/74 (14.9) 1.00
S. aureus 14/38 (36.8) 2.04 0.85-4.92 0.109 8/38 (21.1) 1.29 0.46-3.66 0.628
Strepto. spp. 11/22 (50.0) 2.96 1.05-8.39 0.041 4/22 (18.2) 1.27 0.36-4.48 0.707
Entero. spp. 7/16 (43.8) 3.62 1.11-11.86 0.033 3/16 (18.8) 1.91 0.52-7.01 0.330
Age (years)
 <60 13/78 (16.7) 1.00 8/78 (10.3) 1.00
 ≥60 32/68 (47.1) 4.44 2.07-9.53 0.000 14/68 (20.6) 2.27 0.89-5.80 0.087
Previous ocular surface disease
 No or unknown 26/101 (25.7) 1.00 12/101 (11.9) 1.00
 Yes 19/45 (42.2) 2.10 1.01-4.42 0.049 10/45 (22.2) 2.12 0.84-5.35 0.112
Previous ocular surgery
 No or unknown 34/119 (28.6) 1.00 15/119 (12.6) 1.00
 Yes 11/27 (40.7) 1.71 0.72-4.08 0.220 7/27 (25.9) 2.43 0.88-6.71 0.087
Ocular trauma history
 No or unknown 31/93 (33.3) 1.00 15/93 (16.1) 1.00
 Yes 14/53 (26.4) 0.71 0.34-1.52 0.385 7/53 (13.2) 0.79 0.30-2.08 0.636
Systemic disease
 No or unknown 27/104 (26.0) 1.00 14/104 (13.5) 1.00
 Yes 18/42 (42.9) 2.13 1.01-4.54 0.048 8/42 (19.0) 1.51 0.59-3.93 0.395
Symptom to treatment interval
 ≤1 (week) 29/111 (26.1) 1.00 15/111 (13.5) 1.00
 >1 (week) 16/35 (45.7) 2.38 1.08-5.24 0.031 7/35 (20.0) 1.60 0.59-4.31 0.353
Location of corneal lesion
 Marginal 9/56 (20.0) 1.00 6/56 (10.7) 1.00
 Central 36/90 (40.0) 3.48 1.52-7.97 0.003 16/90 (17.8) 1.80 0.66-4.92 0.251
Size of epithelial defect (mm2)
 <5 12/89 (13.5) 1.00 7/89 (7.8) 1.00
 ≥5 33/57 (57.9) 8.82 3.95-19.72 <0.001 15/57 (26.8) 4.34 1.64-11.47 0.003
Hypopyon
 No 15/105 (14.3) 1.00 4/105 (3.8) 1.00
 Yes 30/41 (73.2) 16.36 6.78-39.49 <0.001 18/41 (43.9) 19.76 6.11-63.94 <0.001
Initial BCVA
 ≥0.1 2/78 (2.6) 1.00 1/78 (1.3) 1.00
 <0.1 43/68 (63.2) 65.36 14.76-289.44 <0.001 21/68 (30.9) 34.40 4.48-264.23 0.001
Epithelial healing time (days)
 <10 3/73 (4.1) 1.00
 ≥10 42/73 (57.5) 31.61 9.10-109.82 <0.001

OR = odds ratio; CI = confidence interval; Strepto. spp. = Streptococcus species; Entero. spp. = Enterococcus species; BCVA = best corrected visual acuity.

* Percentage of eyes which had poor visual outcome of final best corrected visual acuity of 0.1 or less;

Percentage of eyes which had surgical treatment.

Table 5.
Risk factors for poor visual outcome and surgical treatment in Gram-positive bacterial keratitis (multivariate logistic regression analysis*)
Factor Poor visual outcome
Factor Surgical treatment
OR 95% CI p-value OR 95% CI p-value
Age ≥ 60 (years) 1.00 0.22-4.67 0.999 Age ≥ 60 (years) 0.51 0.14-1.88 0.311
Size of epithelial defect ≥5 (mm2) 3.31 0.69-15.85 0.134 Size of epithelial defect ≥ 5 (mm2) 1.35 0.41-4.43 0.617
Hypopyon (+) 4.42 0.98-19.98 0.053 Hypopyon (+) 10.96 2.66-45.18 0.001
Initial BCVA less than 0.1 36.52 6.18-215.81 <0.001 Initial BCVA less than 0.1 11.46 1.32-99.54 0.027
Cultured organism 0.528 Previous ocular surgery (+) 1.82 0.53-6.39 0.351
Strepto. spp. 2.72 0.39-18.77 0.310
Entero. spp. 5.24 0.44-62.54 0.190
Previous ocular surface disease (+) 0.82 0.21-3.21 0.785
Systemic disease (+) 0.86 0.21-3.59 0.840
Symptom to treatment interval >1 week 1.04 0.21-5.15 0.955
Central corneal lesion 0.21 0.32-1.44 0.113
Epithelial healing time ≥ 10 (days) 19.17 3.43-107.22 0.001

OR = odds ratio; CI = confidence interval; BCVA = best corrected visual acuity; Strepto. spp. = Streptococcus species; Entero. spp. = Enterococcus species.

* Multivariate logistic regression analysis was performed for the factors which had p-value less than 0.1 in univariate logistic regression analysis.

TOOLS
Similar articles